Literature DB >> 6430068

Comparison of continuous and intermittent Factor VIII concentrate therapy in hemophilia A.

W E Hathaway, M J Christian, S L Clarke, U Hasiba.   

Abstract

Comparison of continuous versus intermittent (every 12 h bolus) infusion of a high-purity Factor VIII concentrate in 12 severe hemophilia A patients undergoing surgical procedures indicated that a higher (50 u/dl versus 35 u/dl) minimal plasma level was seen with the same amount of product when given continuously. A continuous VIII concentrate infusion of 2 u/kg/h produces a mean VIIIc level of about 50 u/dl or, alternatively, about 0.04 u/kg/h raises the VIIIc level by 1 u/dl (1%). None of the patients showed any abnormal bleeding. Higher plasma levels of VIIIc were noted by the two-stage VIIIc assay than by the one-stage VIIIc assay. Fibrinogen levels were normal or only slightly elevated, and the monomer test was consistently negative.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6430068     DOI: 10.1002/ajh.2830170111

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  9 in total

Review 1.  Management of hemophilia in developing countries.

Authors:  R Kashyap; V P Choudhry
Journal:  Indian J Pediatr       Date:  2001-02       Impact factor: 1.967

Review 2.  Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia.

Authors:  S Björkman; E Berntorp
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

3.  Coronary artery bypass grafting in a patient with hemophilia B: continuous recombinant factor IX infusion as per the Japanese guidelines for replacement therapy.

Authors:  Tomoyuki Suzuki; Shunsuke Kawamoto; Kiichiro Kumagai; Osamu Adachi; Keisuke Kanda; Masaaki Ishikawa; Yoko Okitsu; Hideo Harigae; Shin Kurosawa; Yoshikatsu Saiki
Journal:  Gen Thorac Cardiovasc Surg       Date:  2014-12-19

4.  Progress of in vitro factor VIII coagulant activity from 0 to 8 hours after reconstitution.

Authors:  Ye Jee Shim; Kun Soo Lee; Uk Hyun Kim; Jin Kyung Suh; Sae Yun Baik; Shin Young Hyun
Journal:  Blood Res       Date:  2014-12-23

5.  Cost-utility analysis of primary prophylaxis versus treatment on-demand for individuals with severe haemophilia.

Authors:  Alexander H Miners; Caroline A Sabin; Keith H Tolley; Christine A Lee
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

6.  Low-dose continuous infusion of factor VIII in patients with haemophilia A.

Authors:  Tomaž Prelog; Majda Benedik Dolničar; Lidija Kitanovski
Journal:  Blood Transfus       Date:  2015-11-16       Impact factor: 3.443

Review 7.  Continuous infusion of recombinant activated factor VII: a review of data in congenital hemophilia with inhibitors and congenital factor VII deficiency.

Authors:  Madhvi Rajpurkar; David L Cooper
Journal:  J Blood Med       Date:  2018-11-29

Review 8.  Bone fragility in patients affected by congenital diseases non skeletal in origin.

Authors:  L Masi; S Ferrari; M K Javaid; S Papapoulos; D D Pierroz; M L Brandi
Journal:  Orphanet J Rare Dis       Date:  2021-01-06       Impact factor: 4.123

9.  Continuous Infusion of Factor VIII and von Willebrand Factor in Surgery: Trials with pdFVIII LFB or pdVWF LFB in Patients with Bleeding Disorders.

Authors:  Jerzy Windyga; Benoît Guillet; Lucia Rugeri; Alexandra Fournel; Ewa Stefanska-Windyga; Valérie Chamouard; Sonia Pujol; Céline Henriet; Françoise Bridey; Claude Négrier
Journal:  Thromb Haemost       Date:  2022-05-31       Impact factor: 6.681

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.